Numab to receive milestone payment Boehringer Ingelheim has advanced its novel multi-specific antibody for retinal diseases resulting from a collaboration…
WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the…
WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the…
REDWOOD CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for…
REDWOOD CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for…
Two applicants will each receive a Grant of $50,000 to support the development of outstanding clinical cancer research to improve…
Two applicants will each receive a Grant of $50,000 to support the development of outstanding clinical cancer research to improve…
WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of…
WTX-124 initial Phase 1b expansion arm data showed 30% overall response rate as a monotherapy in a defined subset of…
The combined Company will move forward as Decoy Therapeutics, Inc. and trade on the NASDAQ Stock Market under the ticker…